Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Avicanna ( (TSE:AVCN) ) just unveiled an announcement.
Avicanna Inc. announced a board transition with the resignation of director Paul Fornazzari and the appointment of seasoned capital markets executive and long-time shareholder Michael Kott to its board, effective January 1, 2026. Kott, founder and CEO of CM-Equity AG and now head of a global single-family office, brings more than three decades of experience in international capital markets, governance and cross-border investments, which the company’s leadership expects will support its next stage of growth, scaling efforts and value creation for shareholders amid growing global momentum for evidence-based cannabinoid pharmaceuticals.
The most recent analyst rating on (TSE:AVCN) stock is a Hold with a C$0.22 price target. To see the full list of analyst forecasts on Avicanna stock, see the TSE:AVCN Stock Forecast page.
Spark’s Take on TSE:AVCN Stock
According to Spark, TipRanks’ AI Analyst, TSE:AVCN is a Neutral.
Avicanna’s overall stock score is primarily impacted by its financial performance, which is challenged by negative profitability and cash flow issues. Technical analysis indicates a bearish trend, and valuation metrics are unattractive due to negative earnings. However, recent corporate events provide some optimism for future growth, slightly offsetting the negative aspects.
To see Spark’s full report on TSE:AVCN stock, click here.
More about Avicanna
Avicanna Inc. is a commercial-stage international biopharmaceutical company specializing in the development, manufacturing and commercialization of plant-derived, cannabinoid-based products and formulations for global medical and pharmaceutical markets. Its portfolio spans more than 30 proprietary, evidence-based products across four business pillars: the RHO Phyto medical cannabis formulary in Canada and select international markets; the MyMedi.ca medical cannabis care platform offering diversified products and pharmacist-led patient support; a pharmaceutical pipeline of indication-specific cannabinoid candidates targeting dermatology, chronic pain and neurological disorders; and the Aureus Santa Marta active pharmaceutical ingredients business supplying high-quality CBD, THC and CBG to international partners.
Average Trading Volume: 55,910
Technical Sentiment Signal: Sell
Current Market Cap: C$26.51M
For a thorough assessment of AVCN stock, go to TipRanks’ Stock Analysis page.